2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
You are currently not logged in to PHD
To view this content, please login to your account, or within the login, click 'Create an Account' for guest access. To access AHA's full array of member benefits, join or renew today.
Please note: American Heart Association does not associate with, nor endorse YouTube recommendations.
Steve Ommen, MD, FACC from the Mayo Clinic and Carolyn Ho, MD, FAHA from Brigham and Women's Hospital discuss the 2024 updates to the Hypertrophic Cardiomyopathy (HCM) Guidelines. They highlight the introduction of Mavacamten, the first cardiac myosin inhibitor, as a significant change following its FDA approval for symptomatic obstructive HCM.
Recommended Videos
Key Diagnostic Points from the Kawasaki Disease Statement
Future Directions of Kawasaki Disease
Advancements in the Treatment of Kawasaki Disease
Acute and Long Term Imaging Management for Kawasaki Disease
Updates on Echocardiograms for Measurements of the Coronary Artery in Pati...
Loading...
Save Video
Please note: American Heart Association does not associate with, nor endorse YouTube recommendations.
Video is not available. Please check the URL.